| Literature DB >> 25856221 |
Caroline Ann Gunn1,2, Janet Louise Weber3, Anne-Thea McGill4, Marlena Cathorina Kruger5.
Abstract
Increased consumption of vegetables/herbs/fruit may reduce bone turnover and urinary calcium loss in post-menopausal women because of increased intake of polyphenols and potassium, but comparative human studies are lacking. The main aim was to compare bone turnover markers and urinary calcium excretion in two randomised groups (n = 50) of healthy post-menopausal women consuming ≥ 9 servings of different vegetables/herbs/fruit combinations (three months). Group A emphasised a generic range of vegetables/herbs/fruit, whereas Group B emphasised specific vegetables/herbs/fruit with bone resorption-inhibiting properties (Scarborough Fair Diet), with both diets controlled for potential renal acid load (PRAL). Group C consumed their usual diet. Plasma bone markers, urinary electrolytes (24 h) and estimated dietary PRAL were assessed at baseline and 12 weeks. Procollagen type I N propeptide (PINP) decreased (-3.2 μg/L, p < 0.01) in the B group only, as did C-terminal telopeptide of type I collagen (CTX) (-0.065 μg/L, p < 0.01) in women with osteopenia compared to those with normal bone mineral density (BMD) within this group. Intervention Groups A and B had decreased PRAL, increased urine pH and significantly decreased urinary calcium loss. Urinary potassium increased in all groups, reflecting a dietary change. In conclusion, Group B demonstrated positive changes in both turnover markers and calcium conservation.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25856221 PMCID: PMC4425157 DOI: 10.3390/nu7042499
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Change in urine pH in intervention Groups A and B. Urine pH was second void, fasted and self-reported by intervention participant’s twice weekly using pH dipsticks. Circles are weekly averages of groups (A and B) together. The graph is fitted with a Lowess smoother line demonstrating increasingly alkaline pH.
Intervention and control group diets.
|
| ||||||
|
| Herbs 1 | Fruit 1 | Vegetables 1 | At least 5 servings/day of any vegetable (non Group B); examples of commonly-consumed vegetables | ||
|
| Basil, mint, oregano | Apple | Banana | Other fruit (not citrus or prunes) | Spinach, silver beet, white/green cabbage | Carrot, pumpkin, peas, cauliflower, courgettes, |
| 1 culinary serving | 1 | 1 | 1 | 1 | ||
|
| Herbs | Fruit | Vegetables | Other vegetables (≥2–3 servings from this category) and ≤2 servings self-selected | ||
| Parsley sage, rosemary, thyme, garlic | Prunes | Oranges/other citrus | Other fruit (not banana or apple) | Chinese cabbage, e.g., bok choy, red cabbage, lettuce, rocket | Onions, broccoli, tomatoes, mushrooms, cucumber, leeks, green beans | |
| 1 culinary serving | 1 | 1 | 1 | 1 | ||
1 All serving sizes according to New Zealand Ministry of Health guidelines: fruit/vegetables (F/V) = 50–80 g or 0.5 cup cooked or 1 cup raw (salad greens) or 1 medium fruit, starchy vegetables (135 g); protein includes meat, fish, eggs, nuts/seeds and legumes; herbs are additional to 9 servings of F/V and in teaspoon quantities.
Changes in urinary mineral excretion in the three study groups (A, B, C) from baseline.
| Urinary Mineral Excretion mmol/24 h | Baseline | End | Change | % Change | |||
|---|---|---|---|---|---|---|---|
| Calcium A | 29 | 3.9 ± 2.02 | 29 | 2.7 ± 1.5 2 | −1.2 (−1.8–−0.5) 3 | −26 | 0.002 |
| Calcium B | 36 | 4.8 ± 2.1 | 36 | 3.5 ± 1.8 | −1.3 (−2.0–−0.6) | −24 | 0.001 |
| Calcium C | 22 | 4.2 ± 1.6 | 22 | 3.6 ± 1.6 | −0.61 (−1.6–−0.2) | 2 | 0.14 |
| N/S | <0.05 | ||||||
| Potassium A | 29 | 135 ± 91 | 29 | 221 ± 199 | 86 (−5–167) | 93 | 0.04 |
| Potassium B | 36 | 174 ± 189 | 36 | 260 ± 217 | 85 (−9–178) | 141 | 0.07 |
| Potassium C | 22 | 187 ± 150 | 22 | 291 ± 265 | 104 (−27–235) | 93 | 0.10 |
| NS | NS | ||||||
| Sodium A | 29 | 256 ± 119 | 29 | 90 ± 50 | −164 (−117–−212) | −48 | 0.001 |
| Sodium B | 36 | 274 ± 114 | 36 | 110 ± 64 | −166 (131–−202) | −50 | 0.001 |
| Sodium C | 22 | 260 ± 108 | 22 | 103 ± 54 | −166 (−120–−213) | −49 | 0.02 |
| NS | NS | ||||||
| Magnesium A | 29 | 4.0 ± 1.9 | 29 | 3.9 ± 1.4 | −0.04 (−0.8–0.8) | −28 | 0.9 |
| Magnesium B | 36 | 4.7 ± 1.6 | 36 | 4.4 ± 2.3 | −0.08 (−0.9–0.7) | −5 | 0.9 |
| Magnesium C | 22 | 4.1 ± 1.5 | 22 | 4.3 ± 1.5 | 0.1 (−0.6–0.8) | 10 | 0.8 |
| NS | NS | ||||||
| Creatinine A | 29 | 8929 ± 3191 | 29 | 9881 ± 2999 | 952 (−659–2563) | N/A | 0.2 |
| Creatinine B | 36 | 9017 ± 2591 | 36 | 8344 ± 3279 | −481 (−1992–1029) | N/A | 0.5 |
| Creatinine C | 22 | 9169 ± 2602 | 22 | 10,069 ± 2768 | 899 (−717–2516) | N/A | 0.3 |
| NS |
1 Significance of change between groups determined by ANOVA, except potassium (Kruskal-Wallis); within-group change was determined by Student t-test; 2 baseline and end values show means ± SDs; 3 all change values are means (95% CIs).
Anthropometric and bone mineral density (BMD) characteristics of the study population.
| Characteristics 1 | Group A | Group B | Group C |
|---|---|---|---|
| Age (years) 2 | 60 ± 4 (53–68,60) 2 | 60 ± 4 (51–71,61) | 61 ± 5 (51–71,61) |
| YSM 3 | 11 ± 5 (9–12) | 11 ± 4 (9–12) | 11 ± 5 (9–12) |
| Weight (kg) (baseline) | 72 ± 13 (68–76) | 70 ± 13 (66–73) | 66 ± 11 (63–70) |
| Weight (kg) (end) | 72 ± 12.5 (68–74) | 70 ± 13 (66–73) | 66 ± 11 (62–70) |
| Height (metres) | 1.6 ± .5 (1.61–1.64) | 1.65 ± 7 (1.62–1.167) | 1.63 ± 7 (1.61–1.66) |
| BMI 4 (kg/m2) | 27 ± 5 (26–29) | 25 ± 5 (24–27) | 24 ± 5 (23–26) |
| Body fat % | 40 ± 6.6 (38–42) | 38 ± 7 (36–40) | 37 ± 6 (35–39) |
| BP 5 systolic (mmHg) base | 131 ± 16 (126–135) | 132 ± 18 (127–137) | 129 ± 18 (124–135) |
| BP systolic (mmHg) end | 131 ± 15 (126–135) | 129 ± 17 (125–134) | 127 ± 18 (122–133) |
| BP diastolic(mmHg) base | 80 ± 10 (77–83) | 79 ± 10 (76–81) | 78 ± 9 (75–81) |
| BP diastolic (mmHg) end | 79 ± 10 (76–82) | 79 ± 10 (76–82) | 78 ± 9 (75–80) |
| BMD 6 ( | |||
| Normal BMD (%) | 20 (40) | 16 (32) | 15 (36) |
| Osteopenia (%) | 26 (52) | 26 (52) | 22 (54) |
| Osteoporotic (%) | 4 (8) | 8(16) | 4 (10) |
| Spine BMC (g/cm) | 53 ± 13 (49–57) | 55 ± 10 (52–58) | 55 ± 13 (50–59) |
| Spine BMD (g/cm2) | 0.95 ± 15 (0.90–0.99) | 0.94 ± 14 (0.90–0.98) | 0.97 ± 0.20 (0.90–1.00) |
| Spine | −0.8 ± 1.2 (−1.1–−0.5) | −0.9 ± 1.3 (−1.3–−0.6) | −0.6 ± 1.6 (−1.1–−0.1) |
| Hip BMC (g/cm) | 30 ± 5 (29–32) | 29 ± 5 (28–31) | 30 ± 5 (29–32) |
| Hip BMD (g/cm2) | 0.88 ±11 (0.85–0.91) | 0.86 ± 0.14 (0.82–0.89) | 0.88 ± 0.01 (0.84–0.92) |
| Hip | −0.5 ± 0.9 (−0.8–−0.3) | −0.69 ± 1.1 (−1.0–−0.3) | −0.48 ± 1.0 (−0.8–−0.2) |
| Femoral neck hip BMC (g/cm) | 3.7 ±0.7 (3.5–3.9) | 3.5 ± 0.8 (3.3–3.8) | 3.8 ± 0.6 (3.6–4.0) |
| Femoral neck hip BMD (g/cm2) | 0.76 ± 0.12 (0.72–0.79) | 0.72 ± 0.11 (0.69–0.75) | 0.75 ± 0.12 (0.72–0.79) |
| Femoral neck hip | −0.8 ± 1.0 (−1.2–−0.5) | −1.2 ± 1.0 (−1.5–−0.9) | −0.9 ± 1.1 (−1.2–−0.5) |
1 One-way ANOVA, p < 0.05 considered significant between groups; values are mean ± SD (95% CI), except for age 2, which is mean ± SD (range, median); 3 YSM = years since menopause; 4 Body Mass Index, 5 BP = blood pressure; 6 Bone mineral density; normal: BMD higher than 1 SD below young adult female reference mean (t-score ≥ −1 SD); osteopenia: BMD 1 SD or more below the young female adult mean (−1 < t-score < −2.5 SD); osteoporosis: BMD 2.5 SD or more below the young female adult mean (t-score ≤ −2.5 SD).
Changes in food group servings and estimated dietary PRAL from baseline to the end of the dietary intervention.
| Servings 1 /Day | Group A | Group B | Group C (Control) | |
|---|---|---|---|---|
| Fruit (baseline) 3 | 2.0 ± 0.9 (0–3.8) | 1.8 ± 0 .9 (0.3–3.8) | 2.2 ± 1.2 (0–4.7) | 0.15 |
| Fruit (final) | 2.9 ± 1.4 (0.50–7.0) | 3.0 ± 1.0 (1.3–5.3) | 2.2 ± 1.4 (0–6.3) | 0.003 |
| Change 4 | 0.9 ± 1.5 (−2.3–4.8) | 1.3 ± 1.1 (−0.8–4.0) | −0.06 ± 1.0 (−2.0–2.0) | 0.001 |
| Vegetables (baseline) | 3.4 ± 1.2 (1.3–6.0) | 3.3 ± 1.3 (1.0–7.8) | 3.7 ± 1.3 (1.2–7.0) | 0.21 |
| Vegetables(end) | 5. 5 ± 1.9 (1.7–10) | 6.1 ± 1.9 (2.7–12.2) | 4.0 ± 1.2 (0.7–6.3) | 0.001 |
| Change 4 | 2.0 ± 2.2 (−3.7–7.3) | 2.8 ± 2.1 (−2.5–8.2) | 0.2 ± 1.5 (−3.7–2.8) | 0.001 |
| Bread/cereals (baseline) | 4.5 ± 1.60 (1.0–8.3) | 4.4 ± 1.4 (0.3–7.5) | 4.2 ± 1.4 (1.7–7.5) | 0.54 |
| Bread/cereals (end) | 3.4 ± 1.52 (0.83–7.8) | 3.3 ± 1.5 (0–7.0) | 4.1 ± 0.7 (0.5–8.0) | 0.03 |
| Change | −1.4 ± 1.9 (−5.7–2.3) | −1.2 ± 1.5 (−5.7–1.5) | −0.22 ± 1.5 (−4.7–2.2) | 0.03 |
| Dairy (baseline) | 1.5 ± 0.74 (0.3–2.8) | 1.5 ± 0.9 (0.2–4.2) | 1.8 ± 1 (0.3–5.3) | 0.28 |
| Dairy (end) | 1.3 ± 1.0 (0.0–5.0) | 1.5 ± 0.8 (0.2–3.5) | 1.4 ± 0.0 (0.0–4.5) | 0.77 |
| Change | −0.2 ± 1.0 (−2.0–3.3) | −0.08 ± 0.8 (−2.3–1.7) | −0.4 ± 0.8 (−2.0–1.5) | 0.24 |
| Meat and protein (baseline) | 1.9 ± 0.9 (0.3–4.3) | 1.8 ± 0.8 (0.3–5.0) | 2.0 ± 0.8 (0.5–4.3) | 0.43 |
| Meat and protein (end) | 1.8 ± 1.0 (0.2–4.8) | 1.7 ± 0.8 (0.3–4.0) | 2.0 ± 1.0 (0.2–6.3) | 0.34 |
| Change | −0.1 ± 1.0 (−2.7–2.5) | −0.1 ± 0.9 (−2.0–2.0) | −0.1 ± 1.0 (−2.2–3.8) | 0.99 |
| PRAL (baseline) mEq/day 5 | −0.1 ± 16 (−36–31) | −1.2 ± 15 (−34–26) | −1.8 ± 13 (−43–27) | 0.76 |
| PRAL (end) mEq/day | −17 ± 17 (−45–27) | −23 ± 16 (−65–10) | −3 ± 16 (−36–40) | 0.001 |
| Change 5 | −17± 17 (−55–15) | −22 ± 25 (−65–10) | −1.6 ± 18 (−30–60) | 0.001 |
1 All serving sizes according to New Zealand Ministry of Health guidelines: fruit/vegetables = 50–80 g, or 0.5 cup cooked, or 1 cup raw (salad greens), or 1 medium fruit, starchy vegetables (135 g); protein includes meat, fish, eggs, nuts/seeds and beans; 2 one-way ANOVA; p-values < 0.05 are considered statistically significant; 3 values are means ± SD (minimum and maximum); 4 paired t-test showing significance in changes within each group; 5 PRAL, estimated dietary potential renal acid load expressed in milliequivalents per day (mEq/day) = 0.49 protein (g/day) + 0.037 phosphorus (mg/day) − 0.021 potassium (mg/day) − 0.026 magnesium (mg/day) − 0.013 calcium (mg/day).
Nutrient intake for each group at baseline and changes at 3 months.
| Nutrientse | Group A Intervention | Group B Intervention | Group C Control | EAR 1/AI 2 RDI 3/SDT 4 | |
|---|---|---|---|---|---|
| Baseline | |||||
| Protein (g) 6 | 86 ± 17 (49–128) | 82 ± 18 (46–128) | 83.5 ± 13.6 (56–117) | 37 1/46 3 | |
| Change | 2.2 ± 19 (−67–35) | 2.0 ± 17 (−34–45) | 0.10 ± 16 (−53–35) | 0.8 | |
| Fat (g) | 72 ± 16 (35–98) | 75 ± 14 (47–102) | 74 ± 17 (42–112) | N/A | |
| Change | 2.30 ± 15 (−36–24) | 2 ± 19 (−49–57) | 4 ± 20 (−69–41) | 0.9 | |
| CHO (g) | 220 ± 43 (150–350) | 216 ± 32 (107–275) | 220 ± 41 (132–304) | N/A | |
| Change | 19 ± 72 (−115–195) | 5.2 ± 52 (−148–133) | 6 ± 65 (−155–124) | 0.5 | |
| Fibre (g) | 27 ± 8 (14–50) | 27 ± 8 (12–56) | 28 ± 8 (13–43) | 25 2/28 4 | |
| Change | 5.7 ± 6.6 (−22–7) | 6.4 ± 10.3 (−28–18) | −0.5 ± 0.0 (−24–24) | 0.01 | |
| Folate (μg) | 368 ± 153 (102–812) | 380 ± 225 (151–1646) | 381 ± 134 (205–687) | 400 3/600 4 | |
| Change | 109 ± 213 (−865–447) | 121 ± 250 (−561–1177) | −9 ± 16 (−237–548) | 0.01 | |
| Sodium (mg) | 2345 ± 618 (1261–4046) | 2766 ± 900 (1242–4593) | 2551 ± 979 (947–6405) | 1600 4 | |
| Change | −63 ± 887 (−2466–1566) | −376 ± 943 (−1561–2461) | 24.5 ± 1256 (−2147–3230) | 0.2 | |
| Potassium (mg) | 3695 ± 766 (2400–6261) | 3643 ± 1000 (2013–6902) | 3781 ± 790 (2410–6027) | 2800 2/4700 4 | |
| Change | 935 ± 953 (−3246–775) | 1393 ± 1375 (−5401–2483) | 64 ± 933 (−1758–2414) | 0.001 | |
| Magnesium (mg) | 365 ± 930 (232–694) | 366 ± 105 (208–667) | 385 ± 112 (231–941) | 265 1/320 3 | |
| Change | 73 ± 134 (−548–298) | 54 ± 106 (−285–229) | −20 ± 113 (−143–532) | 0.001 | |
| Calcium (mg) | 850 ± 257 (375–1532) | 872 ± 347 (404–2,166) | 905 ± 270 (396–1632) | 1100 1/1300 3 | |
| Change | 181 ± 353 (−935–635) | 164 ± 41 (−974–1514) | 5 ± 293 (−621–679) | 0.03 |
NZ reference values are the: 1 estimated average requirement (EAR) (50% population requirements); and/or 2 adequate intake (AI); 3 recommended daily intake (RDI) (98% of population); and/or 4 “suggested dietary target” (SDT); 5 one-way ANOVA between groups, p < 0.05 was considered significant; 6 values are means ± standard deviation (SD) (minimum and maximum) or percentages; nutrients energy adjusted (8000 kJ).
Changes in bone markers within each group.
| Bone Markers | Intervention Group A | Intervention Group B | Non Intervention Group C | ||||
|---|---|---|---|---|---|---|---|
| CTX baseline μg/L 2 | 48 | 0.37 (0.34–0.41) | 50 | 0.42 (0.38–0.45) | 43 | 0.39 (0.33–0.45) | 0.4 |
| CTX mid μg/L | 41 | 0.39 (0.35–0.43) | 47 | 0.43 (0.39–0.47) | 0.2 | ||
| CTX final μg/L | 47 | 0.40 (0.36–0.44) | 47 | 0.41 (0.38–0.45) | 39 | 0.40 (0.35–0.46) | 0.8 |
| Change in CTX | 0.03 (0.01–0.03) | −0.01 (−0.03–0.03) | 0.01 (−0.01–0.03) | 0.4 | |||
| P1NP μg/L | 48 | 44.2 (39.8–48.7) | 50 | 49.7 (45.1–54.2) | 43 | 45.0 (39.0–50.8) | 0.2 |
| P1NP mid μg/L | 41 | 43.8 (38.9–48.6) | 47 | 46.7 (42.5–50.9) | 0.4 | ||
| P1NP end μg/L | 47 | 43.3 (39.3–47.3) | 47 | 45.9 (42.4–49.5) | 39 | 46.6 (38.5–54.6) | 0.6 |
| Change in P1NP | −0.9 (−2.4–4.3) | −3.2 (−5.9–0.4) | 1.8 (−3.1–6.6) | 0.2 | |||
1 p-values for group comparisons are derived from ANOVA; 2 values are means (95% CI); p change by Student t-tests. CTX, C-terminal telopeptide of type 1 collagen; P1NP, procollagen type 1 N propeptide.
Figure 2Change in CTX in women with normal bone mineral density or osteopenia. This figure demonstrates the interaction effect of group and bone mineral density status. C-terminal telopeptide of type I collagen (CTX) decreased significantly in the women with increased bone loss (osteopenia) in group (B) compared to the other two groups of women (A, C) with osteopenia.